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Abstract 
Objectives: To review immediate results, patency rates, hemodynamic success, and incidence of concomitant procedures with 
external iliac artery stenting (EIAS). Methods: Demographic features, category and clinical grade, Trans-Atlantic Inter-Society Con­
sensus II classification lesion type, pre- and postprocedure ankle-brachia! indices, and primary patency were compared between 
group I (EIAS without distal revascularization) and group 2 (EIAS with concomitant distal revascularization). Results: No mortality 
and a I 00% immediate technical success rate was recorded in group I (n = 12) and group 2 (n = 24). Eleven patients (30.6%) also 
had stenting of the adjacent common iliac artery. Two thirds of group 2 patients required concomitant femoral or distal revas­
cularization. Condusions: No difference in stent patency rates was found between patients in group I versus group 2. Patients 
requiring EIAS tend to have more diffuse arterial disease necessitating complicated open reconstruction and/or distal revascular­
ization, as well as more proximal iliac stenting. 
Keywords 
stenting, iliac stenting, concomitant procedures 
Introduction 	 December 2007. Thirty-six patients undergoing EIAS, with and 
without concomitant distal revascularization, were included. 
For patients with aortoiliac occlusive disease, surgical revascu­ Demographic features, prevalence of risk factors, category and 
larization has traditionally been the primary method for treat­ clinical grade of vascular lesions (Rutherford classification), 
ing disabling claudication or critical limb ischemia. The TASC lesion type, and pre- and postprocedure ankle--brachial 
success of endovascular therapies directed toward the Trans­ indices (ABis) were recorded. Initial hemodynamic success 
Atlantic Inter-Society Consensus (TASC) A and B lesions has (defined as an increase of the ABI from preprocedure >0.15) 
now been recognized and in most cases regarded as preferable was measured for all patients. The patients were divided into 
to open surgical techniques. 1 While the initial T ASC guidelines 2 groups based on the procedure that was performed: group 1 
recommended an open surgical approach for the more complex (external iliac artery [EIA] stent without any additional proce­
TASC C and D lesions, this has also been challenged in recent dures other than CIAS [n = 12]), and group 2 (EIA stent with a 
reports, which propose an expanded role for endovascular concomitant distal intervention/bypass or a local reconstruction 
therapies in these lesions.2•5 However, not enough emphasis in the groin [n = 24]). The 36 patients were further subdivided 
has been placed on the fact that patients requiring external iliac into 4 subgroups based upon the exact procedure performed 
artery stenting (BIAS) have been noted to also need concomi­ (la) BIA stent only (n = 6); (lb) BIA and common iliac artery 
tant procedures either with common iliac artery stent (CIAS) or (CIA) stent only (n = 6); (2a) EWCIA stent and distal 
with distal revascularization procedures. revascularization, including open or endovascular procedures 
The purpose of this study was to review immediate results, 
patency rates, hemodynamic success, and incidence of conco­
mitant procedures with BIAS at our institution. 
1 Department of Surgery & The Ohio State Heart & Vascular Center, Division 
ofVascular Diseases & Surgery, The Ohio State University College ofMedicine,
Methods Columbus, OH, USA 
A retrospective chart/electronic medical record review in the Corresponding Author: 
Division of Vascular Diseases and Surgery at The Ohio State Bhagwan Satlanl, St# 3018, -456 W. 10th Avenue, Columbus, OH -43210, USA 
University Medical Center was performed from June 2004 to Email: bhagwan.satlani@osumc.edu 
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Figure I • Distribution of risk factor. 
(n = 20); (2b) EWCIA stent and limited procedures consisting 
of mostly femoral endarterectomy with or without patches 
(n = 6). Two patients had both distal revascularization and 
femoral reconstruction. 
Analysis of variance was used to determine whether the 
differences existed in the technical success and primary 
patency rates between the groups. This study was approved 
bythe Institutional Review Boardat the Ohio State University 
Medical Center. 
Results 
The study population consisted of 6 women and 30 men. The 
prevalence ofrisk factors were smoking (67.6%), hyperlipide­
mia (59.5%), coronary artery disease (43%), diabetes (10.8%), 
and hypertension (69.4%; Figure 1). The mean follow-up for 
the entire cohort was 20.9 months (standard deviation ± 19.3). 
Ofthe 36 patients, 11 patients (30.6%) also had stenting of 
the ipsilateral CIA. No mortality was seen and a 100% techni­
cal success rate was recorded in both groups. Patients in group 
2 underwent concomitant 13 femoral-popliteal bypasses and 5 
femoral-femoral bypass procedures. Six (16.6%) patients had 
associated open femoral procedures consisting of endarterect­
omy with or without a patch or a local interposition graft 
(including 2 who had both). 
The Rutherford classification ofdisease showed a predomi­
nance ofcategory 3, class I lesions (n = 21 ). Anatomically, the 
majority ofthe lesions were TASC B (n = 24; Figure 2). Pri­
mary patency, as assessed by life-table analysis, was 100% for 
the first 10 months after intervention (Figure 3). 
Primary patency was also determined in each of the sub­
groups. Primary patency was similar for groups la, 1 b, and 
2b. Group 2a (EI stent and concomitant distal revasculariza­
tion) had primary patency rate similar to the other groups for 
the first 10 months, then declined to 70% thereafter (Figure 4). 
The average preprocedure ABI was 0.63 ± 0.25 and the 
postprocedure ABI was 0.83 ± 0.25. Although the initial 
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Figure 2. Trans-Atlantic Inter-Society Consensus lesions by 
distribution. 
hemodynamic success was no different in groups 1 and 2, there 
was a trend toward a greater improvement in postprocedural 
ABI in group 2. Patients with TASC C lesions in group 2 exhib­
ited a significantly greater improvement in postprocedural ABI 
compared with TASC A and B lesions undergoing the same 
treatment (P < .05). 
Discussion 
Prior to technical advancements in endovascular technology, 
femoral disease extending proximally into the EIA was treated 
with retroperitoneal endarterectomy, unilateral iliofemoral 
bypass, or crossover femoral bypass. Patients with predomi­
nantly unilateral atherosclerotic disease involving the iliofe­
moral system are now uniquely suited to a combined 
approach of iliac artery angioplasty/stenting with or without 
open reconstruction ofthe femoral/profunda artery, sometimes 
with distal revascularization as well. The argument against 
extending iliac stents across the inguinal ligament into the 
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ofour patients also required CIA stenting. In a study by Maurel 
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Figure J, Primary patency rates for all patients undergoing external 
iliac. artery stenting. 
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Figure 4. Primary patency of the subgroups. 
femoral area is that of stent fracture when crossing the inguinal 
ligament as well as intimal hyperplasia due to external forces 
on the vessel. 6 The question remains as to whether external 
iliac disease behaves more like CIA occlusive disease and is 
easily treatable with percutaneous techniques or to infraingu­
inal disease for which open surgical techniques may still be a 
better option. 
The BAS Results Compared With CIA Percutaneous 
Transluminal Angioplasty (PTA)/Stenting 
Because of the widely held belief that EIA PTA/stenting has a 
lower long-term patency compared with CIA PTA/stenting, a 
review of EIA endovascular intervention is reasonable. The 
contiguous disease pattern is such that 73 to 663 of patients 
reported in the literature who underwent EIA stents also 
required CIA angioplasty/stent (Table 1 ). Thirty percentage 
and colleagues, 90 patients treated with EIA stents were 
followed up for a mean of 23 months.7 The primary patency 
rate was 973, 89.7%, and 83.7% at l, 2, and 3 years, respec­
tively. Lee et al compared the results ofEIA and CIA stenting 
in patients with occlusive lesions. 8 In 49 patients with EIA 
lesions, the primary patency rate following treatment was 
933 and 90% versus 883 and 783 for CIA lesions at 1 year 
and 3 years, respectively. Powell et al reported much less favor­
able results after PT A and selective stenting for EIA lesions 
with 47% and 18% primary patency rates at 12 and 36 months, 
respectively.9 There are likely selection biases in some studies 
reporting inferior patency rates with EIA interventions. These 
biases include differences in severity of clinical ischemia, 
stenting techniques, and types of stents. Although our series 
does not directly compare CIA with EIA stents, patency rates 
were not significantly different between patients with EIAS 
alone and those with CIA and EIA stents. 
Influence ofTASC Classification on Outcomes 
The TASC classification provides a standardized method of 
anatomically describing arterial lesions as well as providing a 
common framework for reporting outcomes following treat­
ment. For totally occluded or severe and complex lesions ofthe 
iliac arteries (T ASC C or D), surgical intervention has been rec­
ommended or preferred, whereas endovascular intervention has 
been advocated for TASC A and B lesions.1 The majority of 
patients (663) in our report had TASC B lesions. Although 
patients with T ASC C lesions had significantly greater rise in 
immediate postprocedural ABI (0.27) compared with the other 
2 groups (0.23 for TASC A lesions and 0.26 for TASC B lesions; 
P < .05), there appeared to be no significant difference in 
patency rates. Maurel and colleagues reported that 77. 73 ofEIA 
lesions treated by endovascular means were classified as T ASC 
A and B lesions.7 Like other authors they reported that TASC C 
or D lesions were associated with a much higher risk ofresteno­
sis.10 One of the reasons given for poorer outcomes in some 
series with EIA lesions compared with CIA lesions treated with 
stents is that patients with EIA lesions tend to have more severe 
multisegmental disease (fASC C lesions.) This is supported in 
our current series with one third requiring concomitant CIA 
stenting and two third requiring concomitant distal revasculari­
zation Only 6 patients underwent EIA stenting alone. 
Primary patency has been reported to be significantly lower 
in patients with TASC type C or D lesions.11 In a large series of 
533 CIA and EIA lesions followed for a mean of 72 months, 
693 were classified as TASC A and B, whereas 313 were 
TASC C and D lesions.12 The procedure time and complication 
rate were both higher in the more severe TASC C and D groups. 
However, no significant differences existed in initial and long­
term patency between the 2 groups. 
Whether the presence ofEIA disease, regardless ofseverity, 
is a significant predictor of poor outcomes after angioplasty/ 
stenting in women has been debated7•11 Timaran observed sig­
nificantly worse results in women among a group of67 patients 
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Table I. Incidence of Concomitant Procedures in Patients Undergoing External Iliac Artery Stenting 
Associated lnfrainguinal 
Year No. of Patients Mean Follow-Up Associated Common Associated Open Bypass and/or Distal 
Reported (arteries) (months) Iliac Angioplasty/Stent Femoral Procedures Endovascular Procedures 
Pum• 2011 223 18 N/A 261223 (8.5%) 171223 (7.6%) 
Maurel 2009 90 (107) 23 20190 (22%) 8191 (12%) 2/91 (2%) 
Nelsonb 2002 34 13 4 (12%) 36 (100%) 14 (41%) 
Timaranc 2001 67 (87) 28 45/87 (51%) NIA 551247 (22%) 
Lee 2000 69 (98) 21 7198 (7%) NIA NIA 
Chan( 2008 171 (193) 24 104 (66%) NIA 52 (27%) 
Kashyape 2008 83 (127) 21 N/A 12 (14.4%) 5 (4%) 
Authorsf 2011 36 20.9 11 (30.6%) 6 (16.6%) 20 (55%) 
Abbreviations: El, external iliac; Cl, common iliac; FP, femoral-popliteal; N/A, not available. 
• Serles Included El and Cl lesions. 

b Series only included patients with El stenting and combined common femoral endarterectomy. 

c Series reported additional concomitant procedures in entire cohort (common and external iliac stents). 

d Series only included patients with El and Cl stanting and combined common femoral endarteractomy. 

• Series compared aortofemoral reconstruction with angioplasty/stenting of both El and Cl arteries. 

f Two patients had both associated open procedures and FP/distal endovascular procedures. 

with claudication or critical limb ischemia treated with EIA 
stenting with a primary patency rate of only 61 % and 47% at 
1 and 3 years compared with a global rate of 763 and 563 for 
the entire series. 11 Our numbers are too small to draw any con­
clusions on the influence of gender in our cohort. 
Concomitant Procedures 
Management of concomitant femoral artery and distal 
nfrainguinal disease is an important consideration in patients 
with aortoiliac disease. In a recent report, 503 of patients 
required a local endarterectomy with or without a profunda­
plasty and another 11% needed simultaneous lower extremity 
bypass in patients undergoing an aortofemoral bypass. 13 In the 
same series, comparing open to endovascular intervention, 
213 of the angioplasty/stent group required either femoral 
reconstruction or a bypass. In our experience, 20 patients 
(55%) underwent associated in:frainguinal bypass and/or distal 
endovascular procedures and 6 (16.6%) also had an endarter­
ectomy or an interposition graft. In a similar series of patients 
with EIA stenting, 8 (123) of 91 patients had associated open 
femoral or distal procedures performed7 In a recent report of 
223 interventions for aortoiliac disease, concomitant open sur­
gical procedures were performed in 26 patients (8.5%).14 Eigh­
teen underwent open femoral endarterectomy, 8 femoral­
femoral, and 4 femoral--popliteal bypasses. In addition, an 
associated endovascular procedure involving the femoral/ 
popliteal system was necessary in 17 patients. 
One of the few reported experiences describing results with 
EI stenting combined with concomitant femoral endarterectomy 
was published by Nelson and colleagues.15 Four (123) ofthe 34 
patients in the series also needed CI angioplasty and 14 (413) 
had distal revascularization performed. With a mean follow-up 
period of 13 months, 1-year primary patency and primary­
assisted patency rates were 84% and 97%, respectively. 
The overall experience in patients requiring EIA stenting is 
that a significant number will also require CIA stenting, local 
femoral reconstruction, or distal femoral endovascular or 
bypass procedures. It behooves the vascular surgeon to be pre­
pared to do more than EIA stenting in this group ofpatients. 
Influence ofConcomitant Distal Disease 
The influence of associated distal disease on the clinical out­
come ofiliac revascularization with either open surgical proce­
dures or endovascular methods has been debated Stein 
reported a clinical benefit of 23.3% at 4 years following aorto­
femoral surgical bypass in patients with outflow disease com­
pared with 84% in patients with good outflow.16 Laborde et 
al studied 455 patients comparing patients with aortoiliac dis­
ease, external iliac disease, and multilevel disease to determine 
outcomes.17 The presence of associated distal disease was a 
powerful predictor of unsatisfactory outcomes following iliac 
stent placement. At 3 years, only 60.8% showed clinical suc­
cess compared with 91.6% with aortoiliac/iliac disease and 
97.9% with external iliac disease pattern. Ballard et al exam­
ined the treatment ofTASC type D iliac lesions and found that 
ipsilateral superficial femoral artery occlusion was an indepen­
dent predictor of both bypass graft failure and stent failure.18 
Our experience with patients who require EWCIA stenting 
with concomitant distal revascularization confirms that pri­
mary patency dropped off after the first 10 months in contrast 
to the other 3 subgroups (Figure 4). 
Conclusion 
In summary, our results show good technical and short-term 
success with EIA stenting and concomitant CIA stenting and/ 
or distal revascularization. The use ofendovascular techniques 
for TASC C and D lesions is still debated. The vascular surgeon 
should be prepared to perform a local revascularization or 
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distal procedure to improve outflow at the time ofEIA stenting 
inovertwo thirds ofthis population. In addition, almost one third 
ofpatients needing EIA stenting will need CIA stenting as well. 
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